Page 29 - 09 EMA
P. 29
ndication
tumours, malignant lymphoma or multiple myeloma, and at
risk of transfusion as assessed by the patient's general status
(e.g. cardiovascular status, preexisting anaemia at the start of
chemotherapy).
Silapo can be used to increase the yield of autologous blood from patients
n a predonation programme. Its use in this indication must be balanced
against the reported risk of thromboembolic events. Treatment should
nly be given to patients with moderate anaemia (no iron deficiency), if
blood saving procedures are not available or insufficient when the
cheduled major elective surgery requires a large volume of blood (4 or
more units of blood for females or 5 or more units for males).
Tevagrastim is indicated for the reduction in the duration of neutropenia
and the incidence of febrile neutropenia in patients treated with
stablished cytotoxic chemotherapy for malignancy (with the exception
f chronic myeloid leukaemia and myelodysplastic syndromes) and for
he reduction in the duration of neutropenia in patients undergoing
myeloablative therapy followed by bone-marrow transplantation
onsidered to be at increased risk of prolonged severe neutropenia. The
afety and efficacy of filgrastim are similar in adults and children
eceiving cytotoxic chemotherapy.
Tevagrastim is indicated for the mobilisation of peripheral blood
progenitor cells (PBPC).
n patients, children or adults, with severe congenital, cyclic, or
diopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x
109/l, and a history of severe or recurrent infections, long term
administration of Tevagrastim is indicated to increase neutrophil counts
and to reduce the incidence and duration of infection-related events.
Tevagrastim is indicated for the treatment of persistent neutropenia
ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV
nfection, in order to reduce the risk of bacterial infections when other
ptions to manage neutropenia are inappropriate.
- 15 -
tumours, malignant lymphoma or multiple myeloma, and at
risk of transfusion as assessed by the patient's general status
(e.g. cardiovascular status, preexisting anaemia at the start of
chemotherapy).
Silapo can be used to increase the yield of autologous blood from patients
n a predonation programme. Its use in this indication must be balanced
against the reported risk of thromboembolic events. Treatment should
nly be given to patients with moderate anaemia (no iron deficiency), if
blood saving procedures are not available or insufficient when the
cheduled major elective surgery requires a large volume of blood (4 or
more units of blood for females or 5 or more units for males).
Tevagrastim is indicated for the reduction in the duration of neutropenia
and the incidence of febrile neutropenia in patients treated with
stablished cytotoxic chemotherapy for malignancy (with the exception
f chronic myeloid leukaemia and myelodysplastic syndromes) and for
he reduction in the duration of neutropenia in patients undergoing
myeloablative therapy followed by bone-marrow transplantation
onsidered to be at increased risk of prolonged severe neutropenia. The
afety and efficacy of filgrastim are similar in adults and children
eceiving cytotoxic chemotherapy.
Tevagrastim is indicated for the mobilisation of peripheral blood
progenitor cells (PBPC).
n patients, children or adults, with severe congenital, cyclic, or
diopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x
109/l, and a history of severe or recurrent infections, long term
administration of Tevagrastim is indicated to increase neutrophil counts
and to reduce the incidence and duration of infection-related events.
Tevagrastim is indicated for the treatment of persistent neutropenia
ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV
nfection, in order to reduce the risk of bacterial infections when other
ptions to manage neutropenia are inappropriate.
- 15 -
